No Evidence for the CD31 C/G Gene Polymorphism as an Independent Risk Factor of Coronary Heart Disease

Thromb Haemost 2000; 83(04): 629
DOI: 10.1055/s-0037-1613875

Letters to the Editor

Schattauer GmbH

Authors

Andreas Gardemann

¹Institut für Klinische Chemie und Pathobiochemie
Andreas Knapp

¹Institut für Klinische Chemie und Pathobiochemie
Norbert Katz

¹Institut für Klinische Chemie und Pathobiochemie
Harald Tillmanns

²Abteilung Kardiologie und Angiologie der Justus-Liebig-Universität Giessen, Germany
Werner Haberbosch

²Abteilung Kardiologie und Angiologie der Justus-Liebig-Universität Giessen, Germany

References
1 Serebruany VL, Gurbel PA. Effect of thrombolytic therapy on platelet expression and plasma concentration of PECAM-1 (CD31) in patients with acute myocardial infarction. Arterioscler Thromb Vasc Biol 1999; 19: 153-8.
2 Gumina RJ, Schultz JE, Yao Z, Kenny D, Warltier DC, Newman PJ, Gross GJ. Antibody to platelet/endothelial cell adhesion molecule-1 reduces myocardial infarct size in a rat model of ischemia-reperfusion injury. Circulation 1996; 94: 3327-33.
3 Behar E, Chao NJ, Hiraki DD, Krishnaswamy Brown BW, Zehnder JL, Grumet FC. Polymorphism of adhesion molecule CD31 and its role in acute graft-versus-host disease. N Engl J Med 1996; 334: 286-91.
4 Gardemann A, Lohre J, Katz N, Tillmanns H, Hehrlein FW, Haberbosch W. The 4G4G genotype of the plasminogen activator inhibitor 4G/5G gene polymorphism is associated with the risk and extent of coronary artery disease. Thromb Haemost 1999; 82: 1121-6.